Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,728
  • Shares Outstanding, K 24,951
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,940 K
  • 60-Month Beta 3.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.43
  • Low Estimate -0.48
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +50.83%
on 05/07/20
6.80 -19.71%
on 05/26/20
+1.73 (+46.38%)
since 05/04/20
3-Month
2.55 +114.12%
on 03/17/20
6.80 -19.71%
on 05/26/20
+1.25 (+29.69%)
since 03/04/20
52-Week
2.55 +114.12%
on 03/17/20
15.70 -65.22%
on 07/05/19
-6.33 (-53.69%)
since 06/04/19

Most Recent Stories

More News
Studies Into Psychedelic Drugs Reveal Significant Medical Potential

, /PRNewswire/ -- Psychedelic drugs include a range of substances with varying pharmacological profiles that all have strong effects on the consumer's conscious experience. Such products are borne from...

AMRS : 4.88 (-2.98%)
VFF : 6.15 (-3.45%)
ZYNE : 5.46 (-1.80%)
NUMI.VN : 0.670 (-4.29%)
LKYSD : 0.4922 (-8.00%)
VFF.TO : 8.24 (-3.63%)
NEPT.TO : 4.16 (-2.58%)
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

ZYNE : 5.46 (-1.80%)
Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

- Robust Response Sustained through Two Years of Treatment with Zygel(TM) in Patients from Phase 2 FAB-C Trial -

ZYNE : 5.46 (-1.80%)
Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters...

ZYNE : 5.46 (-1.80%)
Stocks Surge More Than 3% This Week

Stocks Surge More Than 3% This Week

HEXO : 0.7300 (+5.71%)
ZYNE : 5.46 (-1.80%)
KERN : 9.23 (-0.75%)
SPLK : 181.58 (-3.92%)
PANW : 226.69 (-2.88%)
BABA : 218.04 (-0.26%)
MRNA : 60.59 (+1.17%)
Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

Is (ZYNE) Outperforming Other Medical Stocks This Year?

ZYNE : 5.46 (-1.80%)
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 5.46 (-1.80%)
Researchers Delve Into Psychedelics in Search of Novel Therapies

, /PRNewswire/ -- The trend of cannabis legalization in several countries is one of the key factors driving the market's growth. Additionally, the use of cannabis for medical purposes is gaining momentum...

ZYNE : 5.46 (-1.80%)
NLBIF : 0.7350 (+10.76%)
NLB.CN : 1.000 (+12.36%)
CRON : 6.69 (+3.56%)
XXII : 0.8000 (+0.76%)
Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 5.46 (-1.80%)
Dow, S&P Jump Over 3% on Encouraging Vaccine Data

Dow, S&P Jump Over 3% on Encouraging Vaccine Data

CVX : 96.28 (-0.93%)
COG : 19.98 (-1.82%)
SIMO : 45.23 (-2.77%)
GSKY : 5.00 (+8.93%)
AINV : 10.95 (+1.44%)
NVDA : 350.66 (-0.03%)
SDOW : 24.08 (-0.21%)
SPXS : 8.04 (+1.01%)
PLT : 13.66 (-2.50%)
NOMD : 21.08 (-1.03%)
CNX : 9.92 (-1.10%)
FLO : 22.63 (-1.05%)
HUM : 392.27 (-0.37%)
HEXO : 0.7300 (+5.71%)
ZYNE : 5.46 (-1.80%)
CCL : 18.48 (+7.13%)
UAL : 39.10 (+16.20%)
DAL : 32.38 (+13.73%)
LUV : 38.27 (+5.08%)
C : 55.65 (+4.33%)
WFC : 30.22 (+4.82%)
BAC : 26.78 (+3.04%)
JPM : 106.44 (+2.08%)
MRNA : 60.59 (+1.17%)
WMT : 122.11 (-1.10%)
HD : 248.95 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ZYNE with:

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 5.70
1st Resistance Point 5.58
Last Price 5.46
1st Support Level 5.35
2nd Support Level 5.24

See More

52-Week High 15.70
Fibonacci 61.8% 10.68
Fibonacci 50% 9.12
Fibonacci 38.2% 7.57
Last Price 5.46
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar